What happened
Alphabet's Isomorphic Labs has agreed a research partnership with MSD to search for small molecule drug candidates against a cancer target that the companies consider strategically important, Silicon Republic reported. The project brings together the AI technology of Isomorphic Labs and the data resources held by MSD.
Isomorphic Labs will use in silico prediction, meaning computer-simulated experiments, to generate molecule designs, running MSD's data sets through its own drug design engine, IsoDDE. MSD will lead pre-clinical and clinical development, manufacturing and the commercial launch of any resulting medicines. Isomorphic Labs gets an upfront payment and may earn more as specified milestones are reached.
Sarah Skerratt, chief research officer at Isomorphic Labs, said the company would apply its drug design engine to a challenging programme to make significant discovery progress. George Addona, a senior vice-president at MSD Research Laboratories whose remit spans discovery, translational medicine and preclinical development, said effective use of AI and machine learning in molecule design depends on laboratory experiments and computational work being tightly coordinated, and that the pairing aims to produce better candidates faster.
Context
The agreement came in the same week that Isomorphic Labs said it had raised $5bn in Series C funding. Greenoaks and Sequoia Capital co-led the round. Andreessen Horowitz and other new backers also invested, and Alphabet contributed a substantial amount. Earlier supporters Temasek, GV, Thrive Capital, CapitalG, the UK Sovereign AI Fund and MGX also took part.
简报
一封邮件,尽览一周科技要闻。
每周精选值得一读的报道。可随时退订。
